Processa Pharmaceuticals, Inc.

PCSA

US74275C3043

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
2 ^USD	-0.99%		-6.10%	-70.11%

May. 10	Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research	CI

Khalid Islam Not to Stand for Re-Election as Director of Processa Pharmaceuticals, Inc

May 31, 2022 at 08:00 am EDT

Processa Pharmaceuticals, Inc. announced that Dr. Khalid Islam, who served as a director since November 2020 has announced his retirement from the Board and, therefore, informed the Board that he will not stand for reelection at the AGM to be held on July 11, 2022.

Latest news about Processa Pharmaceuticals, Inc.

Processa Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 10	CI
Processa Pharmaceuticals, Inc. Names Steven Cha as Senior Vice President of Clinical Research	Apr. 30	CI
Certain Common Warrants of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	Apr. 29	CI
Certain Restricted Stock Units of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	Apr. 29	CI
Certain Options of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	Apr. 29	CI
Certain Common Stock of Processa Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 30-APR-2024.	Apr. 29	CI
Top Premarket Decliners	Apr. 26	MT
Top Midday Gainers	Apr. 25	MT
HC Wainwright Starts Processa Pharmaceuticals With Buy Rating, $8 Price Target	Apr. 25	MT
Processa Pharmaceuticals, Inc. Presents Two Abstracts At the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1B Trial	Apr. 11	CI
Processa Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Sector Update: Health Care Stocks Stronger Late Afternoon	Jan. 26	MT
Top Midday Decliners	Jan. 26	MT
Sector Update: Health Care Stocks Higher Friday Afternoon	Jan. 26	MT
Processa Pharmaceuticals Prices $7 Million Common Stock Offering	Jan. 26	MT
Sector Update: Health Care Stocks Softer Late Afternoon	Jan. 25	MT
Top Midday Gainers	Jan. 25	MT
Processa Pharmaceuticals Shares More Than Double After Completing Safety Evaluation of Cancer Treatment	Jan. 25	DJ
Processa Pharmaceuticals, Inc. Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses	Jan. 25	CI
Processa Pharmaceuticals Proposes Equity Offering	Jan. 22	MT
Sector Update: Health Care Stocks Steady Late Afternoon	Jan. 19	MT
Sector Update: Health Care	Jan. 19	MT
Processa Plans to Expand NGC-Cap Program Into Breast Cancer; Shares Soar	Jan. 19	MT
Wall Street Set to Open Higher Friday Ahead of Consumer Sentiment, Home Sales Data	Jan. 19	MT
Processa Pharma Shares Jump Premarket After Expansion of NGC-Cap Program	Jan. 19	DJ

Chart Processa Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Processa Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on utilizing its regulatory science approach, including the principles associated with food and drug administration (FDAâs) Project Optimus Oncology initiative and the related FDA Draft Guidance, in the development of Next Generation Chemotherapy (NGC) oncology drug products. The three NGC treatments in its pipeline are NGC-Capecitabine (NGC-Cap), PCS3117, also referred to as NGC-Gemcitabine (NGC-Gem) and PCS11T, also referred to as NGC-Irinotecan (NGC-Iri). NGC-Cap is a combination of PCS6422 and capecitabine, capecitabine being the oral prodrug of the cancer drug 5-fluorouracil. PCS3117 is an oral analog of gemcitabine that is converted to its active metabolite by a different enzyme system than gemcitabine, resulting in a positive response in gemcitabine patients and some gemcitabine treatment-resistant patients. PCS11T is a prodrug of the active metabolite of irinotecan (SN-38).

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

2 USD

Average target price

6 USD

Spread / Average Target

+200.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PROCESSA PHARMACEUTICALS, INC.	-70.11%	5.71M
ELI LILLY AND COMPANY	+32.36%	694B
NOVO NORDISK A/S	+31.16%	593B
JOHNSON & JOHNSON	-1.60%	371B
MERCK & CO., INC.	+20.07%	331B
ABBVIE INC.	+6.04%	290B
ASTRAZENECA PLC	+14.74%	239B
NOVARTIS AG	+10.02%	209B
ROCHE HOLDING AG	-3.23%	209B
AMGEN INC.	+9.27%	169B

Other Pharmaceuticals

Processa Pharmaceuticals, Inc.

Equities

PCSA

US74275C3043

Pharmaceuticals

Khalid Islam Not to Stand for Re-Election as Director of Processa Pharmaceuticals, Inc

Latest news about Processa Pharmaceuticals, Inc.

Chart Processa Pharmaceuticals, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals